Marketing: Page 88
-
Bayer to spin off material science division into separate company
Bayer says goodbye to its three-pillar business model as healthcare takes center stage.
By Nicole Gray • Sept. 19, 2014 -
Instant pleasure: Vivus ED pill wins faster-acting 'on demand' label
FDA blessing in hand, Auxilium can now market Vivus' Stendra as being effective for use a mere 15 minutes before sex.
By Sy Mukherjee • Sept. 18, 2014 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineCommercialization
New drugs for obesity are becoming blockbusters, while Trump administration pressure is reshaping pharma marketing strategies ahead of looming patent cliffs.
By BioPharma Dive staff -
UPDATED: Report: Sovaldi dropout rate 4 times higher than in trials
A CVS Health Corp analysis finds a "plateau and downward trend" in use of Gilead's $1,000-per-pill Hep C cure.
By Sy Mukherjee • Sept. 17, 2014 -
Roche's cheaper vision loss drug just as effective as Novartis' Lucentis
Novartis’ Lucentis and Roche’s Avastin are similarly effective against wet age-related macular degeneration. But only one is approved for treating the condition -- even though the other is far cheaper.
By Nicole Gray • Sept. 16, 2014 -
Gilead to allow Indian generics of pricey Sovaldi in developing nations
The deal covers 91 countries that contain more than half of the global infected population.
By Sy Mukherjee • Sept. 15, 2014 -
Report: Psoriatic arthritis market to cross $3.7 billion by 2023
Decision Resources analysts anticipate a 66% increase in psoriatic arthritis' market value over the next 10 years, largely thanks to biologics.
By Nicole Gray • Sept. 12, 2014 -
Deep Dive
New statin guidelines: Thoughts from a physician on the front lines
“It seems that just about everyone over the age of 65 needs to be on a statin based on the new guidelines,” says Dr. Barry Mennen.
By Nicole Gray • Sept. 11, 2014 -
Sanofi wants kids to game their way to diabetes control
A new app from the French drug giant teaches kids with type 1 diabetes how to live with their condition.
By Sy Mukherjee • Sept. 10, 2014 -
Montgomery County Planning Commission
BMS sues Merck over historic PD-1 cancer drug Keytruda
Merck was first to the finish line with Keytruda approval. But BMS claims it owns the rights to a crucial component of PD-1 inhibition -- and that Merck is in violation of its patent.
By Nicole Gray • Sept. 9, 2014 -
Deep Dive
The statin stumper: Are new cholesterol guidelines prudent or overzealous?
There may be controversy surrounding the guidelines -- but the American Heart Association is counting on the AHA/ACC 2013 guidance to save lives.
By Nicole Gray • Sept. 9, 2014 -
Roche cuts jobs in Spain in response to price controls
Spanish officials have negotiated lower prices for drugs, as well as how much money the government pays for them.
By Nicole Gray • Sept. 4, 2014 -
AstraZeneca's Brilinta falls short in phase IV study
But the trial still identified some upsides to using the drug.
By Nicole Gray • Sept. 3, 2014 -
Novo Nordisk walks away from inflammatory disease R&D
All R&D investment and efforts will now be refocused on Novo’s core business, diabetes.
By Nicole Gray • Sept. 3, 2014 -
Bayer to finally bring world famous 'hangover cure' Berocca to US
The orange-tinted disc contains vitamins, zinc, and caffeine, and is a favorite pick-me-up for consumers in dozens of countries. But its ostensible hangover-curing effect isn't supported by studies.
By Sy Mukherjee • Sept. 2, 2014 -
Deep Dive
The biosimilars are coming: Tackling uncertainty and interchangeability
The Generic Pharmaceutical Association says biosimilar interchangeability "is the engine that drives generic competition." But how do we create a working definition for it?
By Nicole Gray • Aug. 28, 2014 -
FDA
Deep DiveThe biosimilars are coming: Why Basaglar and Zarzio are harbingers of a new pharma landscape
Biosimilars. Follow-on biologics. Subsequent-entry biologics. Call them what you want -- generic versions of branded biologics are a reality. But there's still work to be done on improving these products' approval pathway.
By Nicole Gray • Aug. 27, 2014 -
Mylan introduces generic of Upsher-Smith's Klor-Con
Mylan continues to build its legacy as a generics powerhouse.
By Nicole Gray • Aug. 26, 2014 -
Actavis, UCB Pharma butt heads over generic Neupro
UCB Pharma, the manufacturer of Neupro (rotigotine), is suing Actavis to stop commercialization of rotigotine before the expiration of certain US patents.
By Nicole Gray • Aug. 26, 2014 -
Pfizer, GSK's Viiv Healthcare nabs FDA approval for 3-in-1 HIV drug
Could ViiV's Triumeq outsell Gilead's own triple-combo, Atripla?
By Nicole Gray • Aug. 25, 2014 -
Novartis-funded study shows 75% of asthmatics are at risk
A Novartis-funded survey conducted by Allergy UK finds that patients who think they have mild-to-moderate asthma are dependent on relief inhalers.
By Nicole Gray • Aug. 22, 2014 -
Jordan-based Hikma Pharma posts strong results amidst regional turmoil
Hikma anticipates a more challenging second half of the year because of political turmoil in Sudan, Iraq, and Libya. But its injectables business is going strong in the US.
By Nicole Gray • Aug. 22, 2014 -
Deep Dive
The 4 pharma companies with the highest profit margins [Infographic]
Spoiler alert: they aren't the ones you'd expect.
By Sy Mukherjee • Aug. 22, 2014 -
Hospira wins temporary restraining order against Precedex generics
A federal judge has issued a temporary restraining order blocking the FDA's decision to allow generic versions of Hospira's IV sedative.
By Sy Mukherjee • Aug. 20, 2014 -
Apricus Biosciences launches topical ED treatment in Germany
Hexal AG -- a Sandoz affiliate -- will market Vitaros (alprostadil) in Germany, where the drug will join a $150 million ED market.
By Nicole Gray • Aug. 20, 2014 -
Lilly, Boehringer win tentative FDA approval for Sanofi diabetes biosimilar
The provisional nature of the approval for this long-acting insulin is not based on safety concerns, but rather an ongoing patent-infringement spat with Sanofi.
By Nicole Gray • Aug. 20, 2014
Previous
